Lung Cancer Treatments and Mutations
Most cited papers
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine · 2004 · 11,565 citations
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine · 2016 · 10,276 citations
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine · 2015 · 9,473 citations
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience · 2004 · 9,452 citations
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine · 2015 · 8,551 citations
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine · 2009 · 8,355 citations
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerScience · 2015 · 7,918 citations
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine · 2018 · 6,754 citations
- Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerNew England Journal of Medicine · 2015 · 6,294 citations
- Comprehensive molecular profiling of lung adenocarcinomaNature · 2014 · 5,803 citations
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung CancerNew England Journal of Medicine · 2006 · 5,796 citations
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine · 2017 · 5,640 citations
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFRNew England Journal of Medicine · 2010 · 5,571 citations
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine · 2005 · 5,451 citations
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine · 2002 · 5,254 citations
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung CancerNew England Journal of Medicine · 2017 · 4,715 citations
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience · 2007 · 4,559 citations
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine · 2010 · 4,480 citations
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences · 2004 · 4,371 citations
Metadata from OpenAlex (CC0).